NovaBridge Biosciences is a biotechnology company developing immuno-oncology agents for cancer treatment. The company's pipeline includes givastomig, a bispecific antibody in Phase 1b clinical trials for gastric cancer; ragistomig, a bispecific antibody in Phase 1 trials for solid tumors; and uliledlimab, a CD73 neutralizing antibody. The company also holds a strategic licensing agreement with Ferring International Center SA for FE301, an interleukin-6 inhibitor candidate.
The company operates through multiple collaborations to advance its development programs. Bristol Myers Squibb partners on givastomig development, while ABL Bio, Inc. collaborates on both givastomig and ragistomig. TJ Bio supports uliledlimab development. These partnerships supplement the company's internal capabilities and reduce standalone development burden.
NovaBridge Biosciences maintains a lean operational structure with 32 full-time employees and is headquartered in Rockville, Maryland. The company is incorporated in the Cayman Islands and trades on Nasdaq. Founded in 2014 as I-Mab, the company rebranded to NovaBridge Biosciences in October 2025. The company's geographic focus centers on the United States market for its immuno-oncology candidates.
No 10-K filings found.